Benitec recapitalising after US patent resolution opens up new opportunities
This article was originally published in Scrip
Executive Summary
The Australian gene silencing firm Benitec is planning to raise around Aus$8 million ($8.4 million) in a renounceable rights issue, and plans to use the funds mainly to progress three preclinical therapeutic programmes.